Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells

Pharmacological Research

Volumn 55, Issue 4, 2007, Pages 343-349

  Giovannetti, Elisa ^a   Mey, Valentina ^a   Loni, Lucia ^b   Nannizzi, Sara ^a   Barsanti, Gemma ^b   Savarino, Grazia ^a   Ricciardi, Simona ^a   Del Tacca, Mario ^a   Danesi, Romano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Campo di Marte General Hospital   (Italy)

Author keywords

Apoptosis; Cell cycle modulation; Gemcitabine; Gene expression; Human lymphoid cells

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 5' NUCLEOTIDASE; BISBENZIMIDE; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DIETHYL PYROCARBONATE; DNA POLYMERASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; RIBONUCLEOTIDE REDUCTASE; TETRAHYDROURIDINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER PATIENT; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOFLUOROMETRY; DRUG CYTOTOXICITY; DRUG MECHANISM; GENE EXPRESSION PROFILING; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LYMPHOID CELL; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STAINING;

5'-NUCLEOTIDASE; AGED; ANTIGENS, CD; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPHENOTYPING; JURKAT CELLS; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RNA, MESSENGER; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 34047177069     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2007.01.003     Document Type: Article

References (36)

1. Reiman T., Graham K.A., Wong J., Belch A.R., Coupland R., Young J., et al. Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study. Leukemia 16 (2002) 1886-1887
2. Bass A.J., Gockerman J.P., Hammett E., DeCastro C.M., Adams D.J., Rosner G.L., et al. Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. J Clin Oncol 20 (2002) 2995-3000
3. Nabhan C., Krett N., Gandhi V., and Rosen S. Gemcitabine in hematologic malignancies. Curr Opin Oncol 13 (2001) 514-521
4. Johnson S.A. Nucleosides analogues in the treatment of hematological malignancies. Expert Opin Pharmacother 2 (2001) 929-943
5. Lech-Maranda E., Korycka A., and Robak T. Influence of gemcitabine (2′,2′-difluoro-deoxycytidine) and 2-chlorodeoxyadenosine on growth of normal and leukemic cells in vitro. Eur J Haematol 65 (2000) 317-321
6. Shi Z., Azuma A., Sampath D., Li Y.X., Huang P., and Plunkett W. S-phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res 61 (2001) 1065-1072
7. Huang P., Ballal K., and Plunkett W. Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis. Cancer Res 57 (1997) 3407-3414
8. Steinherz P.G., Seibel N.L., Ames M.M., Avramis V.I., Krailo M.D., Liu-Mares W., et al. Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group. Leuk Lymphoma 43 (2002) 1945-1950
9. Zinzani P.L., Magagnoli M., Bendandi M., Orcioni G.F., Gherlinzoni F., Albertini P., et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 9 (1998) 1351-1353
10. Rizzieri D.A., Bass A.J., Rosner G.L., Gockerman J.P., DeCastro C.M., Petros W.P., et al. Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol 20 (2002) 674-679
11. Galmarini C.M., Mackey J.R., and Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15 (2001) 875-890
12. Stam R.W., den Boer M.L., Meijerink J.P., Ebus M.E., Peters G.J., Noordhuis P., et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 101 (2003) 1270-1276
13. Hubeek I., Stam R.W., Peters G.J., Broekhuizen R., Meijerink J.P., van Wering E.R., et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 93 (2005) 1388-1394
14. Alessi-Severini S., Gati W.P., Belch A.R., and Paterson A.R. Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. Leukemia 9 (1995) 1674-1679
15. Wright A.M., Gati W.P., and Paterson A.R. Enhancement of retention and cytotoxicity of 2-chlorodeoxyadenosine in cultured human leukemic lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibrative nucleoside transport. Leukemia 14 (2000) 52-60
16. Marce S., Molina-Arcas M., Villamor N., Casado F.J., Campo E., Pastor-Anglada M., et al. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 91 (2006) 895-902
17. Giovannetti E., Del Tacca M., Mey V., Funel N., Nannizzi S., Ricci S., et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66 (2006) 3928-3935
18. Richel D.J., Colly L.P., Arkesteijn G.J., Arentsen-Honders M.W., Kerster M.G., ter Riet P.M., et al. Substrate-specific deoxycytidine kinase deficiency in 1-beta-d-arabinofuranosylcytosine-resistant leukemic cells. Cancer Res 50 (1990) 6515-6519
19. Bergman A.M., Pinedo H.M., Jongsma A.P., Brouwer M., Ruiz van Haperen V.W., Veerman G., et al. Decreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem Pharmacol 57 (1999) 397-406
20. Lotfi K., Mansson E., Chandra J., Wang Y., Xu D., Knaust E., et al. Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukemia cell line selected for resistance to etoposide. Br J Haematol 113 (2001) 339-346
21. Schröeder J.K., Kirch C., Flasshove M., Kalweit H., Seidelmann M., Hilger R., et al. Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Leukemia 10 (1996) 1919-1924
22. Kawasaki H., Carrera C.J., Piro L.D., Saven A., Kipps T.J., and Carson D.A. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 81 (1993) 597-601
23. Galmarini C.M., Graham K., Thomas X., Calvo F., Rousselot P., El Jafaari A., et al. Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukaemia. Blood 44 (1998) 1922-1926
24. Iwasaki H., Huang P., Keating M.J., and Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 90 (1997) 270-278
25. Dumontet C., Fabianowska-Majewska K., Mantincic D., Callet Bauchu E., Tigaud I., Gandhi V., et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 106 (1999) 78-85
26. Mansson E., Spasokoukotskaja T., Sallstrom J., Eriksson S., and Albertioni F. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line. Cancer Res 59 (1999) 5956-5963
27. Tosi P., Pellicani A., Zinzani P.L., Magagnoli M., Visani G., and Tura S. In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leucemia cells. Haematologica 84 (1999) 793-798
28. Giovannetti E., Mey V., Nannizzi S., Pasqualetti G., Marini L., Del Tacca M., et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68 (2005) 110-118
29. Waselenko J.K., Grever M.R., Shinn C.A., Flinn Ian W., and Byrd J.C. Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukaemia. Leuk Res 25 (2001) 435-440
30. Santini V., Bernabei P.A., Gozzini A., Scarpini B., Zoccolante A., D'Ippolito G., et al. Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders. Haematologica 82 (1997) 11-15
31. Kroep J.R., Loves W.J., van der Wilt C.L., Alvarez E., Talianidis L., Boven E., et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 1 (2002) 371-376
32. Bergman A.M., Pinedo H.M., and Peters G.J. Determinants of resistance to 2′, 2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5 (2002) 19-33
33. Mansson E., Flordal E., Liliemark J., Spasokoukotskaja T., Elford H., Lagercrantz S., et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol 65 (2003) 237-247
34. Loni L., De Braud F., Zinzani P.L., and Danesi R. Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma. Leuk Lymphoma 44 Suppl. 3 (2003) S115-S122
35. Rots M.G., Willey J.C., Jansen G., Van Zantwijk C.H., Noordhuis P., DeMuth J.P., et al. mRNA expression levels of methotrexate resistance-related proteins in childhood leucemia as determined by a standardized competitive template-based RT-PCR method. Leukemia 14 (2000) 2166-2175
36. Giovannetti E., Mey V., Danesi R., Mosca I., and Del Tacca M. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 10 (2004) 2936-2943